Biogen Idec Inc. (NASDAQ: BIIB) has agreed to acquire privately-held Stromedix Inc. for a total price that could reach $562.5 million. Stromedix is developing “innovative therapies for fibrosis and organ failure.”
Under the terms of the deal, Biogen will pay $75 million in cash and earnouts worth another $487.5 million “based on the achievement of certain development and approval milestones across multiple indications.”
Stromedix has one drug, STX-100, currently entering Phase 2 trials for “patients with idiopathic pulmonary fibrosis (IPF), a debilitating and almost uniformly fatal disease in which patients experience progressive difficulty breathing due to fibrosis (scarring) of the lung.” The company says there are more than 200,000 patients suffering from this condition and that there is currently no FDA-approved treatment for it.
Take This Retirement Quiz To Get Matched With A Financial Advisor (Sponsored)
Take the quiz below to get matched with a financial advisor today.
Each advisor has been vetted by SmartAsset and is held to a fiduciary standard to act in your best interests.
Here’s how it works:
1. Answer SmartAsset advisor match quiz
2. Review your pre-screened matches at your leisure. Check out the
advisors’ profiles.
3. Speak with advisors at no cost to you. Have an introductory call on the phone or introduction in person and choose whom to work with in the future
Take the retirement quiz right here.
Thank you for reading! Have some feedback for us?
Contact the 24/7 Wall St. editorial team.
Editors' Picks
